HUM-MOLGEN archive: HUM-MOLGEN News Alert

___________________________________________________________________________ SiRNA Strategies 6-7 April 2005, Café Royal, London Effective Target Validation, In Vivo and Therapeutic Applications http://hum-molgen.org/cgi-bin/banner1/ads.pl?banner=2005-informa3 High-Level Discussion Platform for Sharing Experimental Knowledge ___________________________________________________________________________ INTERNATIONAL COMMUNICATION FORUM IN HUMAN MOLECULAR GENETICS HUM-MOLGEN News Alert - February 08, 2005 - http://hum-molgen.org DIAGnostics - Clinical Research (professional requests) http://hum-molgen.org/clinical-research/ - Collaboration request (human genetic toxicology) http://hum-molgen.org/bb/Forum2/HTML/000174.html - Post diagnostic request / call for collaboration http://hum-molgen.org/diagnostic-posting or contact admin@hum-molgen.org Genetic News by T.M. D'Souza, F.S. Zollmann http://hum-molgen.org/NewsGen - Call for Assistant News Editors Join our editorial team http://hum-molgen.org/NewsGen/04-2003/msg01.html - International Coalition to Fund Autism Genetics Research An international public/private partnership of government health agencies and private advocacy organizations has committed more than $21 million for research to identify the genes associated with autism spectrum disorders. http://hum-molgen.org/NewsGen/02-2005/msg18.html - New Neurons Born In Adult Rat Cortex NIMH scientists have found newly born neurons that communicate via the chemical messenger GABA (gamma-aminobutyric acid) in adult rat cortex, and striatum. http://hum-molgen.org/NewsGen/02-2005/msg17.html - Bone Density Appears To Recover After Adolescents Discontinue Injected Contraceptive Lower bone density appears to recover in adolescent females once they stop using the injected contraceptive depot medroxyprogesterone acetate (DMPA). http://hum-molgen.org/NewsGen/02-2005/msg16.html - DNA Vaccine Banishes TB A new gene therapy approach could help completely eliminate the infection that causes one of the world's biggest killers - tuberculosis (TB). http://hum-molgen.org/NewsGen/02-2005/msg15.html - No Longer Bird Brains Researchers compared parts of birds' brains with the brains of other animals, including mammals, and concluded that much of a bird's brain are responsible for carrying out advanced functions like those in mammals. http://hum-molgen.org/NewsGen/02-2005/msg14.html - The Truth About Antidepressants And Suicide The current controversy over the link between antidepressants and suicidal behaviour in children shouldn't ignore the risks of not treating the disease. http://hum-molgen.org/NewsGen/02-2005/msg13.html - Seeing The Forest Or The Trees Left- and right-handers also use different parts of the brain to focus on the whole versus the parts of a visual stimulus http://hum-molgen.org/NewsGen/02-2005/msg12.html - New Function For Pacemaker Neurons Circadian pacemaker neurons transmit and modulate visual information to control a rapid behavioral response http://hum-molgen.org/NewsGen/02-2005/msg11.html - Researchers Find New Genes Necessary To Make Embryo New genes with roles in the C. elegans embryo revealed using RNAi of ovary-enriched ORFeome clones http://hum-molgen.org/NewsGen/02-2005/msg10.html - Discovery Promises Simpler Therapy For Sickle Cell Disease Impaired vasodilation by red blood cells in sickle cell disease http://hum-molgen.org/NewsGen/02-2005/msg09.html - Viral DNA Sequence A Possible Trigger For Breast Cancer MMTV Env encodes an ITAM responsible for transformation of mammary epithelial cells http://hum-molgen.org/NewsGen/02-2005/msg08.html - Search and Destroy: A New Mechanism Of Regulating RNA Degradation Mammalian Staufen1 Recruits Upf1 to Specific mRNA 3'UTRs so as to Elicit mRNA Decay http://hum-molgen.org/NewsGen/02-2005/msg07.html - Protein Stops Growth Of Brain Tumor, OHSU Study Shows Herstatin, an autoinhibitor of the epidermal growth factor receptor family, blocks the intracranial growth of glioblastoma http://hum-molgen.org/NewsGen/02-2005/msg06.html - Blood Test Shows Promise As Monitor For Antiangiogenic Cancer Therapy Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis http://hum-molgen.org/NewsGen/02-2005/msg05.html - First U.S. Kidney Cancer Vaccine Trial Underway In the study, patients with stage IV renal cell carcinoma are given regular doses of an investigational kidney cancer vaccine, called Trovax, in conjunction with Interleukin-2 (IL-2). http://hum-molgen.org/NewsGen/02-2005/msg04.html - New Inherited Disease Can Cause Early Aortic Rupture A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. http://hum-molgen.org/NewsGen/02-2005/msg03.html - How Many Comparative Genomes Are Enough? A model of the statistical power of comparative genome sequence analysis. http://hum-molgen.org/NewsGen/02-2005/msg02.html - Scientists Find Genome Structure Responsible for Gene Activation Genomic maps and comparative analysis of histone modifications in human and mouse http://hum-molgen.org/NewsGen/02-2005/msg01.html - Detection of a new blood pressure-increasing hormone Urine adenosine tetraphosphate: a novel endothelium-derived vasoconstrictive factor http://hum-molgen.org/NewsGen/01-2005/msg34.html - Contact Genetic News editors news@hum-molgen.org Literature http://hum-molgen.org/literature/ - New books/writing opportunities Lerner & Lerner is looking for scientists, researchers, and writers for three new English language projects http://hum-molgen.org/literature/01-2005/msg02.html Biotechnical requests and sources http://hum-molgen.org/biotechnology Biomedical Positions http://hum-molgen.org/positions/ - Biochemistry / Immunology: PhD student Charité Medical School, Berlin, 13353, Germany http://hum-molgen.org/positions/predoctoral/0524.html - Biotechnology: QUALITY CONTROL SCIENTIST II - Torrance, California Work Wonders Staffing, LLC, USA http://hum-molgen.org/positions/non_academic_positions/1642.html - Biotechnology: Bilingual Sales Representatives - Torrance, California Work Wonders Staffing, LLC, USA http://hum-molgen.org/positions/non_academic_positions/1641.html - Cancer Research: Postdoctoral Researcher North West Cancer Research Fund Institute, Bangor, LL57 4SG, United Kingdom http://hum-molgen.org/positions/postdocs/2550.html - Cell and Molecular Biology / Anatomy: POST-DOCTORAL INSERM, 75015 Paris France http://hum-molgen.org/positions/postdocs/2548.html - Computational Genetics / Bioinformatics: PHD Position in Computational Biology/Bioinformatics International University Bremen, Bremen, 28759, Germany http://hum-molgen.org/positions/predoctoral/0525.html - Computational Genetics / Bioinformatics: POST-DOCTORAL FELLOW International University Bremen, Bremen, 28759, Germany http://hum-molgen.org/positions/postdocs/2549.html - Medical Research (others): Deputy Laboratory Manager Part Time (Grant Funded) UMDNJ, PISCATAWAY, 08854, USA http://hum-molgen.org/positions/academic_positions/0192.html - Medical Research (others): Postdoctoral Appointee (Grant Funded) UMDNJ, PISCATAWAY, 08854, USA http://hum-molgen.org/positions/postdocs/2546.html - Medical Research (others): Sr. Scientist Materials Product Development Clorox Company, PLEASANTON, 94566 http://hum-molgen.org/positions/non_academic_positions/1646.html - Medical Research (others): Research Grant Manager American Diabetes Association, ALEXANDRIA, 22301 http://hum-molgen.org/positions/non_academic_positions/1643.html - Medical Research (others): Research Teaching Specialist V Temp. Part time (Grant Funded) UMDNJ, PISCATAWAY, 08854 http://hum-molgen.org/positions/academic_positions/0191.html - Medical Research (others): Senior Medical Writer - GloboMax - MD or CA - 290661 ICON Clinical Research, Inc., SAN FRANCISCO, 94101 http://hum-molgen.org/positions/non_academic_positions/1644.html - Medical Research (others): Postdoctoral Appointee (Grant Funded) UMDNJ, PISCATAWAY, 08854, USA http://hum-molgen.org/positions/postdocs/2547.html - Medical Research (others): Senior Medical Writer - GloboMax - MD or CA - 290661 ICON Clinical Research, Inc., HANOVER, 21076, USA http://hum-molgen.org/positions/non_academic_positions/1645.html - Others: team leader in biostatistics/bioinformatics Public Research Center for Health, Luxembourg, L-1911, Luxembourg http://hum-molgen.org/positions/academic_positions/0190.html - Others: team leader Public Research Center for Health, Luxembourg, L-1911, Luxembourg http://hum-molgen.org/positions/academic_positions/0189.html - Physiology / Biophysics: Post-Doctoral Fellow Inst. of Physiology at Ludwig-Maximilians-University (LMU), Mujnich, 80336, Germany http://hum-molgen.org/positions/postdocs/2545.html - Write a position announcement (free) 1) Set up account: http://hum-molgen.de/cgi-bin/positions.pl?register 2) Post position(s): http://hum-molgen.de/cgi-bin/positions.pl?login Events in bioscience and medicine http://hum-molgen.org/meetings/ - Post event http://hum-molgen.de/cgi-bin/meetings.pl?login Registry of Biomedical Companies (945 active entries) http://hum-molgen.org/companies/ Mailing List Administration (Join or leave the list) http://hum-molgen.org/subscribe-na/ Feedback contact admin@hum-molgen.org Advertise at HUM-MOLGEN contact FS Zollmann (dialogue@hum-molgen.org) ___________________________________________________________________________ SiRNA Strategies 6-7 April 2005, Café Royal, London Effective Target Validation, In Vivo and Therapeutic Applications http://hum-molgen.org/cgi-bin/banner1/ads.pl?banner=2005-informa3 High-Level Discussion Platform for Sharing Experimental Knowledge The siRNA Strategies conference will stimulate new thoughts and ideas in the RNAi field, offering you an opportunity to hear innovative information and the latest updates. Companies who are applying RNAi will present case studies on the practical approaches and effective uses that are occurring, and are not always shared. Knowledge will be pooled and ideas investigated through focused discussion topics: • What approach to take to target validation? • Establishing the true impact of off-target effects • Unravelling the different pathways • What can delivery systems achieve? • What are the pros and cons of different chemical modification? • Addressing pharmacokinetics and modification issues for each disease • What do I need for clinical testing of an siRNA compound? ___________________________________________________________________________ -- | INTERNATIONAL COMMUNICATION FORUM IN HUMAN MOLECULAR GENETICS | HUM-MOLGEN - http://hum-molgen.org | (C) 1994-2005